StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note released on Saturday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Up 8.6 %
TTNP stock opened at $4.53 on Friday. The stock’s 50 day simple moving average is $4.95 and its 200 day simple moving average is $5.77. Titan Pharmaceuticals has a 12-month low of $3.57 and a 12-month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- What Investors Need to Know About Upcoming IPOs
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- The Basics of Support and Resistance
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
